Description: This dataset was collected as part of a double-blind, placebo-controlled, randomized clinical trial to determine the effects of intravenous rHuEpo (200U/kg daily for three consecutive days) on measures of platelet and endothelial cell activation, soluble Fas ligand, and peripheral blood mononuclear cell (PBMC) expression of angiogenesis signaling proteins. The study included 44 adults over 21 years of age with ST-segment elevation myocardial infarction (electrocardiographic changes with elevated cardiac enzymes and/or compatible history), treated with successful percutaneous coronary intervention of the culprit lesion (postprocedure Thrombolysis in Myocardial Infarction grade 3 flow), and clinically indicated aspirin (325 mg daily) and clopidogrel therapy (300- to 600- loading dose determined by the attending cardiologist). The subjects were randomized to received intravenous rHuEpo (200U/kg daily for three consecutive days) or matching placebo. The primary safety outcome variables were bleeding time and platelet function assay (PFA) closure time and were determined before the first dose of the study drug, immediately after the dose of the study drug, and 7 days after the last dose. Additional variables collected include soluble P-selectin, von Willebrand factor, complete blood count, and vital signs.

Subject of Study

Subject Domain

Population Age

Adult (19 years - 64 years)

Senior (65 years - 79 years)

Keywords

Restrictions: Application Required

Author Approval Required
Instructions: Please complete the Data Request Form to request access to this dataset. The information included in the form will be sent to the Corresponding Author who will evaluate your request for their data. The Corresponding Author may ask you to provide additional information if necessary.; Access via Data Request Form
Form to request access

Associated Publications

Data Type

Study Type

Interventional

Grant Support: K24 HL004024/NHLBI NIH

UL1 RR024139/NCCR NIH

K24 HL04024/NHLBI NIH
Other Resources: ClinicalTrials.gov
NCT00367991

Effects of recombinant human erythropoietin on platelet activation in acute myocardial infarction